Cytocristin Vincristine Sulphate 1mg/1ml

Cytocristin Vincristine Sulphate 1mg/1ml

Send Inquiry

Each ml contains

  • Vincristine Sulphate IP ¦..............1 mg
  • Mannitol IP...............................100 mg
  • Preservatives
  • Methyl Paraben IP..................0.13% w/v
  • Propyl Paraben IP...................0.02% w/v
  • in water for injection IP......................q.s.


Vincristine sulphate is used either alone or in conjunction with other oncolytic drugs for the treatment of:

Leukemia, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic myelogenous leukaemia.

Malignant lymphomas, including Hodgkin's disease and non-Hodgkin's lymphomas.

Multiple myeloma.

Solid tumors, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas.

Paediatric solid tumors, including Ewing's sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, Wilms' tumor, retinoblastoma and medulloblastoma.

Idiopathic thrombocytopenic purpura. Patients with true ITP refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to Vincristine but the medicinal product is not recommended as primary treatment of this disorder. Recommended weekly doses of Vincristine given for 3 to 4 weeks have produced permanent remissions in some patients. If patients fail to respond after 3 to 6 doses, it is unlikely that there will be any beneficial results with additional doses.


Adults: Usually administered intravenously at weekly intervals; recommended dose is 1.4 to 1.5 mg/m2 up to a maximum weekly dose of 2 mg.

Children: The suggested dose is 1.4 to 2 mg/m2 given on a weekly basis with a maximum weekly dose of 2 mg. For children weighing 10 kg or less the starting dose should be 0.05 mg/kg administered as a weekly intravenous injection.


The concentration of Vincristine Sulphate Injection is 1 mg/mL. Do not add extra fluid to the vial prior to removal of the dose. Withdraw the solution of Vincristine Sulfate Injection, USP into an accurate dry syringe, measuring the dose carefully.


Intrathecal administration is usually fatal.

Patients with the demyelinating form of Charcot-Marie-Tooth syndrome.

Patients who have shown signs of hypersensitivity to Vincristine or to any of the excipients.

Side Effects

Alopecia, sensory loss, paresthesia, difficulty in walking, slapping gait, loss of deep-tendon reflexes, muscle wasting, generalized sensorimotor dysfunction


Store between 2°C and 8°C in refrigerator. Do not freeze. Protect from light.